Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
10 papers
Recent·Most cited
B. H. Liu, M. Liu, S. Radhakrishnan, C. K. Jaladanki, C. Gao, J. Tang, K. Kumari, M. L. Go, K. A. Vu Le, H.-S. Seo, K. Song, X. Tian, F. Li, J. Tan, H. Arthanari, , C. Li
This study identifies a new IMiD-independent drug targeting SALL4's ZFC4 domain, leading to significant tumor growth inhibition in vivo.
bioRxiv · Jan 3, 2024Cancer Biology
K. A. L. Vu, S. Moein, K. Kumari, B. H. Liu, C. Gao, M. Liu, M.-Y. Dai, Z. Liu, F. Li, J. P. Tang, D. Maddalo, D. S. Auld, D. E. Casalena, X. Tian, M. A. Bassal, , L. Chai
The paper identifies a compound that degrades both SALL4 isoforms, overcoming IMiD limitations in liver cancer treatment.
bioRxiv · Jul 7, 2023 · PreprintCancer Biology
B. H. Chua, L. Ferry, C. Domrane, N. Zaal Anuar, A. Wittek, S. Jha, F. Butter, D. G. Tenen, P.-A. Defossez, D. Kappei
The paper identifies E4F1 and ZNF148 as transcriptional activators of the A57C and wildtype TERT promoter, respectively, and shows their role in upregulating TERT transcription and telomerase activity.
bioRxiv · Jan 13, 2023Cancer Biology
H. Tatetsu, M. Watanabe, J. Liu, K. Tokunaga, E. Iwanaga, Y. Komohara, E. Thrash, M. Matsuoka, D. G. Tenen, L. Chai
This study identifies the cellular origin of aberrant SALL4 expression in MDS using mass cytometry, showing it is mainly in HSPC and myeloid lineages, with SALL4/p53 co-expression linked to TP53 mutations.
bioRxiv · Dec 5, 2022Cell Biology
Y. Zhang, M. Bassal, D. Friedrich, S. Ummarino, T. Verbiest, J. Zhang, D. Tenen, A. Haribabu, D. G. Tenen
The paper shows C/EBPα binds RNA via novel domains, recruits to enhancer sites, and promotes Macrophage differentiation by regulating PU.1 expression.
bioRxiv · Oct 20, 2021 · PreprintCell Biology
M. Guo, T. H. M. Chan, O. An, Y. Song, Z. H. Tan, V. H. E. Ng, X. Cao, W. J. Chng, M. Osato, H. Yang, Q. Zhou, L. Chen, D. G. Tenen
This study identifies ADAR2 downregulation in t(8;21) AML and shows its role in suppressing leukemogenesis through RNA editing.
bioRxiv · Oct 18, 2021 · PreprintCancer Biology
E. van der Kouwe, G. Heller, A. Czibere, L. H. Castilla, R. Delwel, A. Di Ruscio, A. K. Ebralidze, M. Forte, L. Kazianka, C. Kornauth, T. Le, K. Lind, I. A. Monteiro Barbosa, A. Pichler, J. A. Pulikkan, , P. B. Staber
The paper shows that CBF fusions in AML activate the PU.1 antisense promoter, reducing sense PU.1 transcription and blocking myeloid differentiation, similar to T-cell differentiation.
Blood · Oct 14, 2021Peer-reviewedCancer Biology
B. Q. Trinh, S. Ummarino, A. K. Ebralidze, E. van der Kouwe, M. A. Bassal, T. M. Nguyen, R. Coffey, D. E. Tenen, E. Fabiani, C. Gurnari, C.-S. Wu, V. E. Angarica, Y. Zhang, L. Ying, H. Yang, , D. G. Tenen
The paper identifies the long noncoding RNA LOUP as a mediator of RUNX1 and RUNX1-ETO effects in t(8;21) AML, showing it promotes myeloid differentiation and inhibits cell growth by regulating PU.1 expression.
bioRxiv · Jul 24, 2020Cancer Biology
J. Kwon, Y. V. Liu, C. Gao, M. A. Bassal, A. I. Jones, J. Yang, Z. Chen, Y. Li, H. Yang, L. Chen, A. Di Ruscio, Y. Tay, L. Chai, D. G. Tenen
This study identifies a mechanism by which pseudogene 5 induces DNA demethylation and reactivates the oncogene SALL4 in hepatocellular carcinoma, linking HBV infection to HCC progression.
bioRxiv · Jul 15, 2020Cancer Biology
K. C. Higa, A. Goodspeed, J. S. Chavez, V. Zaberezhnyy, J. L. Rabe, D. G. Tenen, E. M. Pietras, J. DeGregori
This study shows chronic IL-1β exposure selects for Cebpa-deficient HSPC by promoting myeloid differentiation and repressing stem cell programs, linking chronic inflammation to hematologic disorders.
bioRxiv · Mar 25, 2020Cancer Biology